Artios Pharma

Artios Pharma is a pioneering pharmaceutical company specializing in the development of next-generation DNA Damage Response (DDR) therapies aimed at treating certain devastating cancers. With DNA damage a known cause of cancer, Artios leverages its innovative strategies and technology to specifically target systems that repair DNA, or DDR pathways. The company's mission is rooted in the belief that DDR-targeting therapies could play a substantial role in the treatment of malignant diseases. Known for innovation in DDR drug discovery, Artios has a dedicated team of scientific founders and industry leaders with years-long experience dating back to the inception of DDR steps.

Over the years, the company has developed a comprehensive approach that skews towards exploiting the full swath of DDR-based medication opportunities, thus driving through beyond a single approach such as synthetic lethality. The company's robust pipeline houses drugs such as ART0380 - an orally dosed ataxia telangiectasia and Rad3-related protein (ATR) inhibitor and ART4215 - a Polynomial theta inhibitor. Artios' pharmaceutical arsenal is also fortified with other potential cancer agents like RLT Sensitizers developed in collaboration with Novartis and Nucleases developed with Merck KGaA. These strategic partnerships help underline Artios' commitment to leveraging external expertise where necessary and maximizing the value derived from their discoveries.

Companies like Artios Pharma attract attention due to their potential for significant impact on public healthcare, especially in the context of cancer treatment. Through its breakthrough DDR-based medicines, Artios offers hope for patients battling daunting cancer challanges. The company's commitment to DNA Damage Response, coupled with its strategic partnerships, innovative drug discovery, and robust pipeline, underscores its position as a strong contender in the pharmaceutical industry. Their tireless drive towards developing broadly applicable therapies, designed with the central aim of maintaining the DNA integrity in healthy tissues while inducing damage in cancerous ones, holds promise for drastic shifts in how cancer is treated.

Connect